March 26, 2018 / 5:14 AM / a month ago

BRIEF-Ablynx ‍Announces Topline Results From Phase II Study Of Vobarilizumab

March 26 (Reuters) - ABLYNX NV:

* ‍ANNOUNCES TOPLINE RESULTS FROM PHASE II STUDY OF VOBARILIZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS​

* PHASE II DOSE-RANGING STUDY OF VOBARILIZUMAB DID NOT MEET PRIMARY ENDPOINT OF DOSE RESPONSE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below